Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies

Abstract

Get full access to this article

View all access options for this article.

References

1 Hellwig K Schimrigk S Fischer M . Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656–658.

2 Krumbholz M Pellkofer H Gold R Hoffmann LA Hohlfeld R Kumpfel T . Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331–1333.

3 Leussink VI Lehmann HC Hartung HP Gold R Kieseier BC . Type III systemic allergic reaction to natalizumab. Arch Neurol 2008; 65: 851–852.

4 Miller DH Khan OA Sheremata WA . International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.

5 Phillips JT O'Connor PW Havrdova E . Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006; 67: 1717–1718.

6 Polman CH O'Connor PW Havrdova E . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

7 Rudick RA Stuart WH Calabresi PA . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

8 Calabresi PA Giovannoni G Confavreux C . MPH For the AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391–1403.